{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:53:48Z","timestamp":1758815628315},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,7,11]],"date-time":"2006-07-11T00:00:00Z","timestamp":1152576000000},"content-version":"vor","delay-in-days":7041,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[1987,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ten chronic lymphocytic leukemia patients were treated with partially pure alpha interferon (IFN\u2010\u03b1) at doses ranging from 3\u20109 \u00d7 10<jats:sup>6<\/jats:sup> units administered intramuscularly daily. Of these patients, three patients with disease stages 0, 1, and 3 (and prolymphocytic leukemia), respectively, responded with partial remissions lasting from 10 to 24+ months; four additional patients had minor responses. Among those responding, modulation of B cell chronic lymphocytic leukemia, surface immunoglobulins, and surface antigens were observed in four patients. These changes included a decline in the proportion of B cells bearing surface immunoglobulin without change in the number of the B cells. Likewise, a decline in the proportion of B cells bearing T\u20101 antigen was observed in three patients. Increase in the percentage of T cells, primarily the T helper cells, was seen in two of the responding patients. Specific binding of \u03b1 interferon was demonstrated prior to therapy in CLL cells of all patients. This binding declined rapidly following treatment with IFN \u03b1.<\/jats:p><jats:p>Induction of the enzyme 2\u2032 5\u2032 oligoisoadenylate synthetase was examined in CLL patients prior to and during therapy with IFN\u2010\u03b1. Variable levels of the enzyme were induced in all patients on therapy; however, only minimal induction was observed in two of three patients failing therapy.<\/jats:p>","DOI":"10.1002\/ajh.2830240403","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T11:10:45Z","timestamp":1172056245000},"page":"341-350","source":"Crossref","is-referenced-by-count":32,"title":["Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia\u2010a pilot study"],"prefix":"10.1002","volume":"24","author":[{"given":"M.","family":"Talpaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rosenblum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Reuben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gutterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,11]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198401053100104"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb07576.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90097-4"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-93-3-399"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1182\/blood.V58.4.712.712","article-title":"Follow\u2010up observations on the effect of human leukocyte interferon in non\u2010Hodgkin's lymphoma","volume":"58","author":"Louie AC","year":"1981","journal-title":"Blood."},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197812282992608"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1128\/jvi.49.2.490-496.1984","article-title":"Synergistic antiviral and antiproliferative activities of E. coli derived human alpha, beta, and gamma interferons","volume":"49","author":"Czarniecki C","year":"1983","journal-title":"J Gen Virol"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910360105"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/6.2.767"},{"key":"e_1_2_1_12_2","first-page":"4848","article-title":"In vivo sensitivity and resistance of chronic myelogenous leukemia cells to \u03b1\u2010interferon: Correlation with receptor binding and induction of 2\u2032 5\u2032 oligoadenylate synthetase","volume":"46","author":"Rosenblum MG","year":"1986","journal-title":"Cancer Res"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90429-2"},{"key":"e_1_2_1_14_2","unstructured":"HuangA LaszloJ BrenckmanW TuttleR WhisnantJ:Lymphoblastoid interferon (Wellferon) trial in chronic lymphocytic leukemia in progressive phase. Proc AACR. Abstr #441 March 1982."},{"key":"e_1_2_1_15_2","first-page":"310","article-title":"Recombinant leukocyte \u03b1\u2010interferon in B\u2010cell chronic lymphocytic leukemia: In vivo effects on autologous antitumor immunity","volume":"4","author":"Schulof RS","year":"1985","journal-title":"J Biol Response Mod"},{"key":"e_1_2_1_16_2","first-page":"67","article-title":"Treatment of lymphoid neoplasias with interferon. II. Human leucocyte \u03b1\u2010interferon in chronic lymphatic leukemia (CLL). Phase I\u2010II trial","volume":"2","author":"Misset JL","year":"1982","journal-title":"Anticancer Res"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.2.128"},{"key":"e_1_2_1_18_2","first-page":"1","article-title":"Surface markers in chronic lymphoid leukemias of B cell type","volume":"22","author":"Caligaris\u2010Cappio F","year":"1985","journal-title":"Semin Hematol"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900030405"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.2.137"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.V67.1.152.152","article-title":"Chronic B\u2010lymphocytic leukemia cells proliferate and differentiate following exposure to interferon in vitro","volume":"67","author":"Ostlund L","year":"1986","journal-title":"Blood"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00917136"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.2830240403","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.2830240403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T07:04:28Z","timestamp":1697958268000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.2830240403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1987,4]]}},"alternative-id":["10.1002\/ajh.2830240403"],"URL":"https:\/\/doi.org\/10.1002\/ajh.2830240403","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[1987,4]]}}}